The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

What are the most promising CAR T therapies in development for multiple myeloma?

The Multiple Myeloma Hub are pleased to present a series of expert interviews from the 61st American Society of Hematology (ASH) meeting in Orlando, US. In this video, Nina D. Shah, University of California, San Francisco, US, answers the question: What are the most promising CAR T therapies in development for multiple myeloma?

Dr Shah comments on some of the exciting abstracts due to be presented at the ASH meeting including; data from a longer follow-up of the LEGEND-2 trial in China, and the US equivalent trial, CARTITUDE, as well as an update from the bb21217 trial. Dr Shah also highlights an abstract on the use of a gamma secretase inhibitor, in combination with anti-BCMA CAR T, in order to increase BCMA expression on the myeloma-cell surface to improve efficacy.

Additionally, Dr Shah adds that there are more CAR T trials than ever before, with other strategies to improve efficacy including the targeting of multiple antigens. Lastly, Dr Shah notes that whilst it is not a CAR T product, some of the new bispecific T-cell engagers (BiTEs) are not given as a continuous infusion and therefore may represent another patient-friendly immunotherapy option.

What are the most promising CAR T therapies in development for multiple myeloma?

Share: